Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) major shareholder Marcin Czernik unloaded 4,389 shares of the stock on the open market in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $38.08, for a total transaction of $167,133.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Karyopharm Therapeutics (NASDAQ:KPTI) traded down 2.47% during mid-day trading on Wednesday, hitting $37.85. 169,234 shares of the company’s stock traded hands. Karyopharm Therapeutics has a 1-year low of $15.50 and a 1-year high of $47.98. The stock’s 50-day moving average is $36.34 and its 200-day moving average is $34.61. The company’s market cap is $1.237 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.02) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.50) by $0.52. On average, analysts predict that Karyopharm Therapeutics will post $-2.19 earnings per share for the current fiscal year.

A number of research firms have recently commented on KPTI. Analysts at Leerink Swann cut their price target on shares of Karyopharm Therapeutics from $63.00 to $60.00 in a research note on Friday, August 8th. Analysts at Oppenheimer downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. One investment analyst has rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $52.67.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.